CVM

AMEX CEL-SCI Corporation
Oct 1, 2026 · 4:27 PM ET LAST TRADE Market Closed

$2.09 ↑ +0.00 (+0.00%) Trading Up from the previous close of $2.09, $0.21 below the day’s high of $2.30

YTD change
-60.27%
vs 20-day SMA
+27.79%
vs 200-day SMA
-28.09%

Price ranges

Previous day
$1.78 $2.09
open $1.80 close $2.06
+$0.26 (+14.44%)
Today
$1.96 $2.30
open $2.06 now $2.09
+$0.03 (+1.46%)
Past week
$1.67 $2.09
from $1.68 now $2.09
+$0.41 (+24.40%)
Past month
$1.46 $2.09
from $1.61 now $2.09
+$0.48 (+29.81%)
This year
$0.89 $6.75
from $5.26 now $2.09
-$3.17 (-60.27%)

Price & Performance

-1.37 (-39.94%) / 6M

$0.6564$2.19$3.73$5.27Apr 1Jul 1Sep 30

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Very Good
  • The stock is 99.8% away from all-time highs of $1,227.30
  • CVM is down 60% since the beginning of the year
  • CVM is down 79% over the past 12 months
  • CVM is up 30% over the past 1 month
  • 4% of all CVM investors are betting against CVM
  • Number of investors short CVM has gone down 21% versus last month

CVM reads very good: price sits above one of the two key moving averages, short interest is falling month over month, the 12-month move is -79.3%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.47
Earnings momentum N/A Quarterly EPS growth
Quarterly change N/A

Valuation

P/E ratio N/A
Enterprise value $26.3M
Beta 1.04

Balance sheet & scale

IncomeN/A
RevenueN/A
Cash$6.5M
Debt$7.9K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeAMEX
Sector Manufacturing
Sub Sector Chemical Manufacturing
Market cap $36.8M

CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Competitor comparison

TickerCompany PriceChange
CSLLY CSL Limited Sponsored ADR $31.94 +0.09%
ARGX argenx SE Sponsored ADR $958.91 -1.21%
ONC BeOne Medicines Ltd. Sponsored ADR $365.94 +0.18%
WXXWY WuXi Biologics (Cayman) Inc. Unsponsored ADR $14.30 +4.99%
INCY Incyte Corporation $121.35 -1.50%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.